Skip to main content


Firm News

Mayer Brown represents Adaptimmune in its $104 million Series A Financing

29 September 2014

Mayer Brown represented leading biotechnology company Adaptimmune Limited on its $104 million Series A financing round led by a group of leading public and private healthcare focused venture funds. UK-based Adaptimmune is focused on the use of T cell therapy with engineered T cell receptors to treat cancer and infectious disease and plans to use the proceeds from the Series A financing to advance the company’s internal programmes into the clinic in multiple cancer indications. The company has clinical operations in Oxford, UK where University of Oxford is a longstanding shareholder and at the University of Pennsylvania.

The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities – partners Todd Bowen (New York) and Richard Smith (London) and senior associate Megan Paul (London); Tax Transactions & Consulting – partners Jason Bazar (New York) and James Hill (London) and senior associate Benjamin Fryer (London) and associate Jared Goldberger (New York); and Employment & Benefits – partner Andrew Stanger (London).

Related Information

  • Related People
    Richard Smith
    T +44 20 3130 3849
    Jason S. Bazar
    T +1 212 506 2323
    James Hill
    T +44 20 3130 3227
    Andrew Stanger
    Legal Professional / Consultant
    T +44 20 3130 3934
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.